The concern of generic rivalry has long loomed around copyright’s famous drug, Sildenafil, triggering questions about the prospects of similar drug stakes. While initial years saw substantial returns, the exclusivity end has allowed the path for discounted copies, potentially reducing revenue and creating a real hazard for shareholders seeking sa